ClinicalTrials.Veeva

Menu
O

Optimed Research, LTD | The Boster Center for Multiple Sclerosis

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Ocrelizumab
Frexalimab
Tolebrutinib
SAR441344
BIIB091
SAR442168
PERSEUS
Tyrosine

Parent organization

This site is a part of Optimed Research, LTD

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 8 total trials

A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

This is a Phase 3 extension, global, multicenter study to assess the long-term safety and tolerability of tolebrutinib in adult participants (aged ≥1...

Enrolling
Secondary Progressive Multiple Sclerosis
Relapsing Multiple Sclerosis
Drug: Teriflunomide
Drug: Placebo

In this study, researchers will learn more about a study drug called BIIB091 in participants with MS who may be experiencing relapses. It is a 2-part...

Enrolling
Relapsing Forms of Multiple Sclerosis
Drug: BIIB091
Drug: DRF

The main objectives of the study are to demonstrate pharmacokinetics (PK) similarity between ABP 692 and Ocrelizumab (US), and ABP 692 and Ocrelizuma...

Enrolling
Relapsing-remitting Multiple Sclerosis (RRMS)
Drug: Ocrelizumab (EU)
Drug: Ocrelizumab (US)

The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral do...

Enrolling
Multiple Sclerosis
Drug: Activated charcoal
Drug: Cholestyramine

The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the dis...

Enrolling
Multiple Sclerosis
Drug: Frexalimab
Drug: Placebo

Primary Objective:To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in primary progressive multiple scler...

Active, not recruiting
Primary Progressive Multiple Sclerosis
Drug: Tolebrutinib
Drug: Placebo

Trial sponsors

Sanofi logo
Amgen logo
Biogen logo
Yale University logo
I

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems